Prescribing patterns and healthcare costs of gout

Curr Med Res Opin. 2019 Jun;35(6):1051-1058. doi: 10.1080/03007995.2018.1552577. Epub 2019 Jan 3.

Abstract

Objective/methods: The Longitudinal Health Insurance Database (LHID) 2010 was used to identify gout cases and their number of gout flares.

Results: Out of 21,376 gout patients, a total of 3561 (16.7%) had frequent gout flares (≥3 gout flares/year). Average all-cause healthcare utilization (35.9 visits vs. 30.7 visits; p < .001) and gout-related utilization (22.7 visits vs. 15.6 visits; p < .001) were higher in frequent gout flare patients than in those with infrequent gout flares. The median gout-related cost (USD $369 vs. $285; p < .001), but not all-cause costs (p = .25), were higher in frequent gout flare patients compared to the infrequent group. Over 55.8% of the flares were treated with colchicine + NSAIDs.

Conclusions: In conclusion, patients with frequent gout flares had higher healthcare utilization and gout-related healthcare costs. Colchicine + NSAIDs are commonly used therapy for gout flare.

Keywords: Gout; Taiwan; costs; prescribing patterns.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Colchicine / therapeutic use
  • Female
  • Gout / drug therapy*
  • Health Care Costs*
  • Humans
  • Male
  • Middle Aged
  • Patient Acceptance of Health Care
  • Practice Patterns, Physicians'
  • Retrospective Studies

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Colchicine